A non-canonical Hippo pathway represses the expression of deltaNp63
A. M. Low-Calle, H. Ghoneima, N. Ortega, A. M. Cuibus, C. Katz, D. Tong, C. Prives, R. Prywes
Abstract
The p63 transcription factor, a member of the p53 family, plays an oncogenic role in squamous cancers, while in breast cancers its expression is often repressed. In the canonical conserved Hippo pathway, known to play a complex role in regulating growth of cancer cells, the protein kinases MST1/2 and LATS1/2 act sequentially to phosphorylate and inhibit the YAP/TAZ transcription factors. We found that in the MCF10A mammary epithelial cell line as well as in squamous and breast cancer cell lines, expression of {Delta}Np63 RNA and protein is strongly repressed by inhibition of the Hippo pathway protein kinases in a manner that is independent of p53. While MST1/2 and LATS1 are required for p63 expression, the next step of the pathway, namely phosphorylation and degradation of the YAP/TAZ transcriptional activators is not required for repression of p63. This suggests that regulation of p63 expression occurs by a non-canonical version of the Hippo pathway. We additionally identified additional genes that were similarly regulated suggesting the broader importance of this pathway. Interestingly, we observed that experimentally lowering p63 expression leads to increased YAP protein levels, thereby constituting a feedback loop. These results, which reveal the intersection of the Hippo and p63 pathways, may prove useful for the control of their activities in cancer cells. One Sentence SummaryRegulation of p63 expression occurs by a non-canonical version of the Hippo pathway in mammary epithelial, breast carcinoma and head and neck squamous carcinoma cells
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A noncanonical repressor function of JUN restrains YAP activity and suppresses YAP-dependent liver cancer growth
Yuliya V. Kurlishchuk, Anita Cindric Vranesic, … Björn von Eyß·bioRxiv·Aug 20, 2023
- The JNK and Hippo pathways control epithelial integrity and prevent tumour initiation by regulating an overlapping transcriptome
Katrina A. Mitchell, Joseph H.A. Vissers, … Kieran F. Harvey·bioRxiv·Jun 19, 2024
- Yorkie-independent negative feedback couples Hippo pathway activation with Kibra degradation
Sherzod A. Tokamov, Ting Su, … Richard G. Fehon·eLifePeer-reviewed·Feb 8, 2021
- Inactivation of the Hippo Tumor Suppressor Pathway Promotes Melanoma
M. A. Vittoria, N. M. Kingston, … N. J. Ganem·bioRxiv·May 4, 2021
- The Hippo pathway effector YAP inhibits NF-kB signaling and ccRCC growth by opposing ZHX2
Xu Li, Yong Suk Cho, … Jin Jiang·Journal of Biological ChemistryPeer-reviewed·Mar 20, 2025
- Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a potential therapeutic target in YAP/TAZ-active cancers